ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.02, Bloomberg Earnings reports. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The company had revenue of $556.69 million for the quarter, compared to analysts’ expectations of $557.68 million. During the same period in the previous year, the company posted $0.74 EPS. ResMed’s revenue was up 7.3% compared to the same quarter last year.

Shares of ResMed (RMD) traded up 0.38% during mid-day trading on Friday, reaching $73.07. 529,536 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $75.87 and a 200-day moving average price of $72.42. The company has a market capitalization of $10.39 billion, a P/E ratio of 30.45 and a beta of 0.83. ResMed has a 1-year low of $56.59 and a 1-year high of $79.63.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 21st. Shareholders of record on Thursday, August 17th will be given a $0.35 dividend. This is an increase from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $1.40 annualized dividend and a yield of 1.92%. ResMed’s dividend payout ratio (DPR) is 58.09%.

RMD has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of ResMed from a “hold” rating to a “sell” rating in a research note on Wednesday, June 28th. BMO Capital Markets reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, May 12th. Citigroup Inc. lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. Jefferies Group LLC restated a “sell” rating and issued a $56.00 target price on shares of ResMed in a report on Friday, April 28th. Finally, BidaskClub upgraded shares of ResMed from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Four research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $65.63.

In other ResMed news, Director Richard Sulpizio sold 24,390 shares of ResMed stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $73.85, for a total value of $1,801,201.50. Following the transaction, the director now directly owns 28,819 shares of the company’s stock, valued at approximately $2,128,283.15. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brett Sandercock sold 1,250 shares of ResMed stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $71.02, for a total value of $88,775.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 204,650 shares of company stock valued at $15,516,845. Corporate insiders own 1.97% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of RMD. Dimensional Fund Advisors LP increased its position in shares of ResMed by 1.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 364,186 shares of the medical equipment provider’s stock valued at $22,599,000 after buying an additional 6,742 shares in the last quarter. UBS Asset Management Americas Inc. increased its position in shares of ResMed by 0.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 372,441 shares of the medical equipment provider’s stock valued at $23,110,000 after buying an additional 1,952 shares in the last quarter. Gulf International Bank UK Ltd increased its position in shares of ResMed by 1.8% in the first quarter. Gulf International Bank UK Ltd now owns 42,044 shares of the medical equipment provider’s stock valued at $3,025,000 after buying an additional 725 shares in the last quarter. National Pension Service increased its position in shares of ResMed by 37,521.7% in the first quarter. National Pension Service now owns 140,329 shares of the medical equipment provider’s stock valued at $10,036,000 after buying an additional 139,956 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of ResMed by 21.2% in the first quarter. Bank of Montreal Can now owns 175,344 shares of the medical equipment provider’s stock valued at $12,619,000 after buying an additional 30,703 shares in the last quarter. 60.66% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “ResMed Inc. (RMD) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/08/19/resmed-inc-rmd-issues-earnings-results-updated-updated.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.